About Ikarovec
Established in 2018, Ikarovec is developing novel, differentiated gene therapies for major ophthalmic indications. Its lead product, a bicistronic gene therapy for geographic atrophy, is in preclinical studies, and earlier programmes are targeting wet-form age-related macular degeneration (AMD), diabetic macular oedema and intraocular hypertension. Building on intellectual property spun-out of Quethera (bought by Astellas in 2018), Ikarovec was founded by UKI2S and recently raised a £2.5m seed round with co-funding from LifeArc and Parkwalk Advisers. There is an experienced senior management team in place with business development and commercial success in ophthalmology and gene therapy – Dr. Peter Widdowson (ex Quethera) is Founder and Chief Technology Officer, and Piers Morgan (ex UniQure) is Executive Chairman.
- Founding: 2018
- Focus : Manufacturer
- Industry : Biotechnology, Pharma
Here you will find Ikarovec
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
